Search

Your search keyword '"Blohmer J"' showing total 538 results
Start Over Author "Blohmer J"
538 results on '"Blohmer J"'

1. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)

Author

Meyer-Wilmes, P., Huober, J., Untch, M., Blohmer, J.-U., Janni, W., Denkert, C., Klare, P., Link, T., Rhiem, K., Bayer, C., Reinisch, M., Bjelic-Radisic, V., Zahm, D.M., Hanusch, C., Solbach, C., Heinrich, G., Hartkopf, A.D., Schneeweiss, A., Fasching, P., Filmann, N., Nekljudova, V., Holtschmidt, J., Stickeler, E., and Loibl, S.

Published
2024
Full Text
View/download PDF

7. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

Author

Karn, T., Denkert, C., Weber, K.E., Holtrich, U., Hanusch, C., Sinn, B.V., Higgs, B.W., Jank, P., Sinn, H.P., Huober, J., Becker, C., Blohmer, J.-U., Marmé, F., Schmitt, W.D., Wu, S., van Mackelenbergh, M., Müller, V., Schem, C., Stickeler, E., Fasching, P.A., Jackisch, C., Untch, M., Schneeweiss, A., and Loibl, S.

Published
2020
Full Text
View/download PDF

8. Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany

Author

Dimitrova, D., Naghavi, B., Richter, R., Nasser, S., Chekerov, R., Braicu, E. I., David, M., Blohmer, J., Inci, G., Torsten, U., Oskay-Özcelik, G., Blau, I., Fersis, N., Holzgreve, A., Keil, E., Keller, M., Keilholz, U., and Sehouli, J.

Published
2021
Full Text
View/download PDF

9. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Author

Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W.D., von Minckwitz, G., Thomalla, J., Kümmel, S., Rautenberg, B., Fasching, P.A., Weber, K., Rhiem, K., Denkert, C., and Schneeweiss, A.

Published
2019
Full Text
View/download PDF

11. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Author

Loibl, S., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Wiebringhaus, H., Kümmel, S., Warm, M., Paepke, S., Just, M., Hanusch, C., Hackmann, J., Blohmer, J.-U., Clemens, M., Dan Costa, S., Gerber, B., Engels, K., Nekljudova, V., von Minckwitz, G., and Untch, M.

Published
2017
Full Text
View/download PDF

13. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Author

von Minckwitz, G., Loibl, S., Untch, M., Eidtmann, H., Rezai, M., Fasching, P.A., Tesch, H., Eggemann, H., Schrader, I., Kittel, K., Hanusch, C., Huober, J., Solbach, C., Jackisch, C., Kunz, G., Blohmer, J.U., Hauschild, M., Fehm, T., Nekljudova, V., Gerber, B., Gnauert, K., Heinrich, B., Prätz, T., Groh, U., Tanzer, H., Villena, C., Tulusan, A., Liedtke, B., Blohmer, J.-U., Mau, C., Potenberg, J., Schilling, J., Just, M., Weiss, E., Bückner, U., Wolfgarten, M., Lorenz, R., Doering, G., Feidicker, S., Krabisch, P., Deichert, U., Augustin, D., Kast, K., Nestle-Krämling, C., Höß, C., Terhaag, J., Fasching, P., Staib, P., Aktas, B., Kühn, T., Khandan, F., Möbus, V., Stickeler, E., Heinrich, G., Wagner, H., Abdallah, A., Dewitz, T., Emons, G., Belau, A., Rethwisch, V., Lantzsch, T., Thomssen, C., Mattner, U., Nugent, A., Müller, V., Noesselt, T., Holms, F., Müller, T., Deuker, J.-U., Strumberg, D., Uleer, C., Solomayer, E., Runnebaum, I., Link, H., Tomé, O., Ulmer, H.-U., Conrad, B., Feisel-Schwickardi, G., Schumacher, C., Steinmetz, T., Bauerfeind, I., Kremers, S., Langanke, D., Kullmer, U., Ober, A., Fischer, D., Kohls, A., Weikel, W., Bischoff, J., Freese, K., Schmidt, M., Wiest, W., Sütterlin, M., Dietrich, M., Grießhammer, M., Burgmann, D.-M., Rack, B., Salat, C., Sattler, D., Tio, J., von Abel, E., Christensen, B., Burkamp, U., Köhne, C.-H., Meinerz, W., Graßhoff, S.-T., Decker, T., Overkamp, F., Thalmann, I., Sallmann, A., Beck, T., Reimer, T., Bartzke, G., Deryal, M., Weigel, M., Weder, P., Steffens, C.-C., Lemster, S., Stefek, A., Ruhland, F., Hofmann, M., Schuster, J., Simon, W., Kronawitter, U., Clemens, M., Janni, W., Latos, K., Bauer, W., Roßmann, A., Bauer, L., Lampe, D., Heyl, V., Hoffmann, G., Lorenz-Salehi, F., Hackmann, J., and Schlag, R.

Published
2014
Full Text
View/download PDF

18. 168P Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)

Author

Huober, J., primary, Janni, W., additional, Untch, M., additional, Blohmer, J-U., additional, Zahm, D-M., additional, Hanusch, C., additional, Jackisch, C., additional, Heinrich, G., additional, Schneeweiss, A., additional, Denkert, C., additional, Link, T., additional, Rhiem, K.E., additional, Furlanetto, J., additional, Solbach, C., additional, Klare, P., additional, Nekljudova, V., additional, Filmann, N., additional, and Loibl, S., additional

Published
2022
Full Text
View/download PDF

19. 200TiP A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa

Author

Loibl, S., primary, Reinisch, M., additional, Denkert, C., additional, Fasching, P.A., additional, Seiler, S., additional, Link, T., additional, Hanusch, C., additional, Bjelic-Radisic, V., additional, Schneeweiss, A., additional, Huober, J., additional, Jackisch, C., additional, Rhiem, K.E., additional, Untch, M., additional, Solbach, C., additional, Blohmer, J-U., additional, Buechele, T., additional, Nekljudova, V., additional, and Loi, S., additional

Published
2022
Full Text
View/download PDF

20. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: Results of a companion protocol of the randomized, NOGGO–AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy

Author

Braicu, E.I., Fotopoulou, C., Chekerov, R., Richter, R., Blohmer, J., Kümmel, S., Stamatian, F., Yalcinkaya, I., Mentze, M., Lichtenegger, W., and Sehouli, J.

Published
2013
Full Text
View/download PDF

22. 358P Everolimus or ribociclib in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and circulating tumor cells: Results from DETECT IVa

Author

Fehm, T.N., Schochter, F., Rack, B., Wimberger, P., Paluchowski, M. Banys, Neubauer, H., Wiesmueller, L., Meier-Stiegen, F., Fasching, P.A., Blohmer, J-U., Hartkopf, A.D., Heublein, S., Huober, J., Riethdorf, S., Pantel, K., Schneeweiss, A., Friedl, T.W.P., Mueller, V., and Janni, W.

Published
2024
Full Text
View/download PDF

23. 350MO Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer – Second interim efficacy analysis of the randomized phase III DETECT V trial

Author

Janni, W., Fehm, T.N., Mueller, V., de Gregorio, A.M.B., Decker, T., Hartkopf, A.D., Just, M., Sagasser, J., Schmidt, M., Wimberger, P., Engler, T., Paluchowski, M. Banys, Fasching, P.A., Rack, B., Schneeweiss, A., Blohmer, J-U., Huober, J., Pantel, K., Friedl, T.W.P., and Schochter, F.

Published
2024
Full Text
View/download PDF

27. Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”

Author

Loibl, S., primary, Untch, M., additional, Burchardi, N., additional, Huober, J., additional, Sinn, B.V., additional, Blohmer, J.-U., additional, Grischke, E.-M., additional, Furlanetto, J., additional, Tesch, H., additional, Hanusch, C., additional, Engels, K., additional, Rezai, M., additional, Jackisch, C., additional, Schmitt, W.D., additional, von Minckwitz, G., additional, Thomalla, J., additional, Kümmel, S., additional, Rautenberg, B., additional, Fasching, P.A., additional, Weber, K., additional, Rhiem, K., additional, Denkert, C., additional, and Schneeweiss, A., additional

Published
2022
Full Text
View/download PDF

29. Risikofaktoren der implantatbasierten, netzunterstützten Brustrekonstruktion – 2-Jahres follow up Daten der Patient Reported Outcome Studie (PRO Bra Trial)

Author

Paepke, S., additional, Klein, E., additional, Faridi, A., additional, Ankel, C., additional, Meiré, A., additional, Gerber-Schäfer, C., additional, Baumann, K., additional, Blohmer, J.-U., additional, Mau, C., additional, Nolte, E., additional, Sander, M., additional, and Thill, M., additional

Published
2022
Full Text
View/download PDF

30. Intelligente vakuum-assistierte Biopsie zur Identifikation von Brustkrebspatientinnen mit pathologischer Komplettremmission (ypT0, ypN0) nach neoadjuvanter Systemtherapie für den Verzicht einer Operation von Brust und Axilla

Author

Pfob, A., additional, Sidey-Gibbons, C., additional, Rauch, G., additional, Thomas, B., additional, Schäfgen, B., additional, Kuemmel, S., additional, Reimer, T., additional, Hahn, M., additional, Thill, M., additional, Blohmer, J.-U., additional, Hackmann, J., additional, Malter, W., additional, Bekes, I., additional, Friedrichs, K., additional, Wojcinski, S., additional, Joos, S., additional, Paepke, S., additional, Degenhardt, T., additional, Rom, J., additional, Rody, A., additional, van Mackelenbergh, M., additional, Banys-Paluchowski, M., additional, Große, R., additional, Reinisch, M., additional, Karsten, M., additional, Golatta, M., additional, and Heil, J., additional

Published
2022
Full Text
View/download PDF

31. Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers

Author

Ortmann, Olaf, Blohmer, J.-U., Sibert, N. T., Brucker, S., Janni, W., Wöckel, A., Scharl, A., Dieng, S., Ferencz, J., Inwald, E. C., Wesselmann, S., Kowalski, C., Denisjuk, E., Csorba, R., Rezek, D., Peschel, S., Denschlag, D., Schad, F., Dieterle, D., Lex, B., Rieger, L., Flock, F., Cramer, A., Strittmatter, H.-J., Bettscheider, J., Lindner, C., Stefek, A., Pauker, W., Hönig, A., Schrauder, M., Seeger, D., Kleine-Tebbe, A., Bleimehl, A., Groh, U., Gebauer, G., Vollert, H.-W., Zorr, A., Friedmann, W., Krabisch, P., Fritz, S., Schwämmle, A., Lucke, W., Schmatloch, S., Heyl, W., Deuschle, P., Arfsten, M., Scheler, P., Ruf-Dördelmann, A., Brückner, B., Bauer, L., Koch, M., Monner, J., Nixdorf, A., Merte, A., Beldermann, F., Felberbaum, R., De Wilde, R. L., Bolkenius, P., Lebrecht, A., Solomayer, E.-F., Hartmann, S., and Hartkopf, A.

Subjects
ddc:610, Early breast cancer · Neoadjuvant chemotherapy · Breast cancer centers · Guidelines · Oncobox research, 610 Medizin, skin and connective tissue diseases
Abstract

Neoadjuvant chemotherapy (NACT) is frequently used in patients with early breast cancer. Randomized controlled trials have demonstrated similar survival after NACT or adjuvant chemotherapy (ACT). However, certain subtypes may benefit more when NACT contains regimes leading to high rates of pathologic complete response (pCR) rates. In this study we analyzed data using the OncoBox research from 94,638 patients treated in 55 breast cancer centers to describe the current clinical practice of and outcomes after NACT under routine conditions. These data were compared to patients treated with ACT. 40% of all patients received chemotherapy. The use of NACT increased over time from 5% in 2007 up to 17.3% in 2016. The proportion of patients receiving NACT varied by subtype. It was low in patients with HR-positive/HER2-negative breast cancer (5.8%). However, 31.8% of patients with triple-negative, 31.9% with HR-negative/HER2-positive, and 26.5% with HR-positive/HER2-positive breast cancer received NACT. The rates of pCR were higher in patients with HR-positive/HER2-positive, HR negative/HER2-positive and triple-negative tumors (36, 53 and 38%) compared to HR-positive/HER2-negative tumors (12%). PCR was achieved more often in HER2-positive and triple-negative tumors over time. This is the largest study on use and effects of NACT in German breast cancer centers. It demonstrates the increased use of NACT based on recommendations in current clinical guidelines. An improvement of pCR was shown in particular in HER2-positive and triple-negative breast cancer, which is consistent with data from randomized controlled trails.

Published
2022

32. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy

Author

Weber, W.P. Shaw, J. Pusic, A. Wyld, L. Morrow, M. King, T. Mátrai, Z. Heil, J. Fitzal, F. Potter, S. Rubio, I.T. Cardoso, M.-J. Gentilini, O.D. Galimberti, V. Sacchini, V. Rutgers, E.J.T. Benson, J. Allweis, T.M. Haug, M. Paulinelli, R.R. Kovacs, T. Harder, Y. Gulluoglu, B.M. Gonzalez, E. Faridi, A. Elder, E. Dubsky, P. Blohmer, J.-U. Bjelic-Radisic, V. Barry, M. Hay, S.D. Bowles, K. French, J. Reitsamer, R. Koller, R. Schrenk, P. Kauer-Dorner, D. Biazus, J. Brenelli, F. Letzkus, J. Saccilotto, R. Joukainen, S. Kauhanen, S. Karhunen-Enckell, U. Hoffmann, J. Kneser, U. Kühn, T. Kontos, M. Tampaki, E.C. Carmon, M. Hadar, T. Catanuto, G. Garcia-Etienne, C.A. Koppert, L. Gouveia, P.F. Lagergren, J. Svensjö, T. Maggi, N. Kappos, E.A. Schwab, F.D. Castrezana, L. Steffens, D. Krol, J. Tausch, C. Günthert, A. Knauer, M. Katapodi, M.C. Bucher, S. Hauser, N. Kurzeder, C. Mucklow, R. Tsoutsou, P.G. Sezer, A. Çakmak, G.K. Karanlik, H. Fairbrother, P. Romics, L. Montagna, G. Urban, C. Walker, M. Formenti, S.C. Gruber, G. Zimmermann, F. Zwahlen, D.R. Kuemmel, S. El-Tamer, M. Vrancken Peeters, M.J. Kaidar-Person, O. Gnant, M. Poortmans, P. de Boniface, J. and Weber, W.P. Shaw, J. Pusic, A. Wyld, L. Morrow, M. King, T. Mátrai, Z. Heil, J. Fitzal, F. Potter, S. Rubio, I.T. Cardoso, M.-J. Gentilini, O.D. Galimberti, V. Sacchini, V. Rutgers, E.J.T. Benson, J. Allweis, T.M. Haug, M. Paulinelli, R.R. Kovacs, T. Harder, Y. Gulluoglu, B.M. Gonzalez, E. Faridi, A. Elder, E. Dubsky, P. Blohmer, J.-U. Bjelic-Radisic, V. Barry, M. Hay, S.D. Bowles, K. French, J. Reitsamer, R. Koller, R. Schrenk, P. Kauer-Dorner, D. Biazus, J. Brenelli, F. Letzkus, J. Saccilotto, R. Joukainen, S. Kauhanen, S. Karhunen-Enckell, U. Hoffmann, J. Kneser, U. Kühn, T. Kontos, M. Tampaki, E.C. Carmon, M. Hadar, T. Catanuto, G. Garcia-Etienne, C.A. Koppert, L. Gouveia, P.F. Lagergren, J. Svensjö, T. Maggi, N. Kappos, E.A. Schwab, F.D. Castrezana, L. Steffens, D. Krol, J. Tausch, C. Günthert, A. Knauer, M. Katapodi, M.C. Bucher, S. Hauser, N. Kurzeder, C. Mucklow, R. Tsoutsou, P.G. Sezer, A. Çakmak, G.K. Karanlik, H. Fairbrother, P. Romics, L. Montagna, G. Urban, C. Walker, M. Formenti, S.C. Gruber, G. Zimmermann, F. Zwahlen, D.R. Kuemmel, S. El-Tamer, M. Vrancken Peeters, M.J. Kaidar-Person, O. Gnant, M. Poortmans, P. de Boniface, J.

Abstract

Aim: Demand for nipple- and skin- sparing mastectomy (NSM/SSM) with immediate breast reconstruction (BR) has increased at the same time as indications for post-mastectomy radiation therapy (PMRT) have broadened. The aim of the Oncoplastic Breast Consortium initiative was to address relevant questions arising with this clinically challenging scenario. Methods: A large global panel of oncologic, oncoplastic and reconstructive breast surgeons, patient advocates and radiation oncologists developed recommendations for clinical practice in an iterative process based on the principles of Delphi methodology. Results: The panel agreed that surgical technique for NSM/SSM should not be formally modified when PMRT is planned with preference for autologous over implant-based BR due to lower risk of long-term complications and support for immediate and delayed-immediate reconstructive approaches. Nevertheless, it was strongly believed that PMRT is not an absolute contraindication for implant-based or other types of BR, but no specific recommendations regarding implant positioning, use of mesh or timing were made due to absence of high-quality evidence. The panel endorsed use of patient-reported outcomes in clinical practice. It was acknowledged that the shape and size of reconstructed breasts can hinder radiotherapy planning and attention to details of PMRT techniques is important in determining aesthetic outcomes after immediate BR. Conclusions: The panel endorsed the need for prospective, ideally randomised phase III studies and for surgical and radiation oncology teams to work together for determination of optimal sequencing and techniques for PMRT for each patient in the context of BR © 2022 The Authors

Published
2022

33. A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)-GeparPiPPa

Author

Loibl, S., Reinisch, M., Denkert, C., Fasching, P. A., Seiler, S., Link, T., Hanusch, C., Bjelic-Radisic, V., Schneeweiss, A., Huober, J., Jackisch, C., Rhiem, K. E., Untch, M., Solbach, C., Blohmer, J-U., Buechele, T., Nekljudova, V., Loi, S., Loibl, S., Reinisch, M., Denkert, C., Fasching, P. A., Seiler, S., Link, T., Hanusch, C., Bjelic-Radisic, V., Schneeweiss, A., Huober, J., Jackisch, C., Rhiem, K. E., Untch, M., Solbach, C., Blohmer, J-U., Buechele, T., Nekljudova, V., and Loi, S.

Published
2022

34. Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)

Author

Huober, J., Janni, W., Untch, M., Blohmer, J-U., Zahm, D-M., Hanusch, C., Jackisch, C., Heinrich, G., Schneeweiss, A., Denkert, C., Link, T., Rhiem, K. E., Furlanetto, J., Solbach, C., Klare, P., Nekljudova, V., Filmann, N., Loibl, S., Huober, J., Janni, W., Untch, M., Blohmer, J-U., Zahm, D-M., Hanusch, C., Jackisch, C., Heinrich, G., Schneeweiss, A., Denkert, C., Link, T., Rhiem, K. E., Furlanetto, J., Solbach, C., Klare, P., Nekljudova, V., Filmann, N., and Loibl, S.

Published
2022

35. Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)

Author

Reinisch, M., Blohmer, J-U., Link, T., Just, M., Untch, M., Stoetzer, O., Fasching, P. A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Thill, M., Jackisch, C., Rhiem, K., Solbach, C., Hanusch, C., Denkert, C., Engels, K., Nekljudova, V., Loibl, S., Reinisch, M., Blohmer, J-U., Link, T., Just, M., Untch, M., Stoetzer, O., Fasching, P. A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Thill, M., Jackisch, C., Rhiem, K., Solbach, C., Hanusch, C., Denkert, C., Engels, K., Nekljudova, V., and Loibl, S.

Published
2022

36. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study (vol 30, pg 1279, 2019)

Author

Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J. -U., Grischke, E. -M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W. D., von Minckwitz, G., Thomalla, J., Kuemmel, S., Rautenberg, B., Fasching, P. A., Weber, K., Rhiem, K., Denkert, C., Schneeweiss, A., Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J. -U., Grischke, E. -M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W. D., von Minckwitz, G., Thomalla, J., Kuemmel, S., Rautenberg, B., Fasching, P. A., Weber, K., Rhiem, K., Denkert, C., and Schneeweiss, A.

Published
2022

38. 58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment

Author

Marmé, F., primary, Hanusch, C., additional, Furlanetto, J., additional, Morris, P., additional, Link, T., additional, Denkert, C., additional, Fasching, P.A., additional, Jackisch, C., additional, Antolín, S., additional, Solbach, C., additional, Aftimos, P., additional, Huober, J., additional, Untch, M., additional, Balic, M., additional, Reinisch, M., additional, Blohmer, J-U., additional, Gonçalves, A., additional, Rey, J., additional, Büchele, T., additional, and Loibl, S., additional

Published
2022
Full Text
View/download PDF

39. 120P AXSANA (AXillary Surgery After NeoAdjuvant Treatment) EUBREAST-3: An international prospective multicenter cohort study to evaluate different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655)

Author

Ruf, F., primary, Kühn, T., additional, Hartmann, S., additional, de Boniface, J., additional, Gentilini, O.D., additional, Stickeler, E., additional, Cakmak, G.K., additional, Rubio, I., additional, Niinikoski, L., additional, Kontos, M., additional, Murawa, D., additional, Bonci, E-A., additional, Hauptmann, M., additional, Thill, M., additional, Markus, H., additional, Lux, M.P., additional, Appelgren, M., additional, Blohmer, J-U., additional, Untch, M., additional, and Banys-Paluchowski, M., additional

Published
2022
Full Text
View/download PDF

40. 94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)

Author

Reinisch, M., primary, Blohmer, J-U., additional, Link, T., additional, Just, M., additional, Untch, M., additional, Stötzer, O., additional, Fasching, P.A., additional, Schneeweiss, A., additional, Wimberger, P., additional, Seiler, S., additional, Huober, J., additional, Thill, M., additional, Jackisch, C., additional, Rhiem, K., additional, Solbach, C., additional, Hanusch, C., additional, Denkert, C., additional, Engels, K., additional, Nekljudova, V., additional, and Loibl, S., additional

Published
2022
Full Text
View/download PDF

43. 199TiP Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA

Author

Marmé, F., primary, Hanusch, C., additional, Furlanetto, J., additional, Denkert, C., additional, Link, T., additional, Untch, M., additional, Blohmer, J-U., additional, Jackisch, C., additional, Reinisch, M., additional, Rhiem, K.E., additional, Schneeweiss, A., additional, Solbach, C., additional, Schöllhorn, L., additional, Fasching, P.A., additional, Rey, J., additional, and Loibl, S., additional

Published
2021
Full Text
View/download PDF

46. PREcoopERA Window-of-Opportunity trial of giredestrant+/- triptorelin vs. anastrozole+triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.

Author

Bjelic-Radisic, V., Munzone, E., Untch, M., Denkert, C., Hirmas, N., Reinisch, M., Solbach, C., Marmé, F., Link, T., van Mackelenbergh, M., Rhiem, K., Langanke, D., Blohmer, J.-U., Reimer, T., Huober, J., Rack, B., Oskay-Öczelik, G., Regan, M., Dubsky, P., and Loibl, S.

Published
2024
Full Text
View/download PDF

47. Additional file 1 of Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany

Author

Dimitrova, D., Naghavi, B., Richter, R., Nasser, S., Chekerov, R., Braicu, E. I., David, M., Blohmer, J., Inci, G., Torsten, U., Oskay-Özcelik, G., Blau, I., Fersis, N., Holzgreve, A., Keil, E., Keller, M., Keilholz, U., and Sehouli, J.

Abstract

Additional file 1: Supplemental Table 1. Distribution of study participants according to the way of recruitment. Supplemental Table 2. Factors predicting the possibility for not being offered or not participating in a clinical trial.

Published
2021
Full Text
View/download PDF

48. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Author

Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W. D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R. K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J-U, Loibl, S., Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W. D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R. K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J-U, and Loibl, S.

Abstract

Background: The efficacy and toxicity of olaparib as combination therapy in early breast cancer (BC) patients with homologous recombinant deficiency (HRD) [score high and/or germline (g) or tumour (t) BRCA1/2 mutation] is not well described. GeparOLA (ClinicalTriais gov, NCT02789332) investigated olaparib in combination with paclitaxel in HER2-negative early BC with HRD. Patients and methods: Patients with untreated primary HER2-negative cT2-cT4a-d or cT1c with either cN + or pNSIN + or cT1c and triple-negative breast cancer (TNBC) or cT1c and Ki-67>20% BC with HRD were randomised either to paclitaxel (P) 80 mg/m(2) weekly plus olaparib (0) 100 mg twice daily for 12 weeks or P plus carboplatinum (Cb) area under the curve 2 weekly for 12 weeks, both followed by epirubicin/cyclophosphamide (EC). Stratification factors were hormone receptor (HR) status (HR versus HR ) and age (<40 versus >= 40 years). The primary endpoint was pathological complete response (pCR; ypTO/is ypNO). A two-sided one-group chi(2)-test was planned to exclude a pCR rate of <= 55% in the PO-EC arm. Secondary end points were other pCR definitions, breast conservation rate, clinical/ imaging response, tolerability and safety. Results: A total of 107 patients were randomised between September 2016 and July 2018; 106 (PO N = 69; PCb N = 37) started treatment. Median age was 47.0 years (range 25.0-71.0); 36.2% had cT1, 61.0% cT2, 2.9% cT3, and 31.8% cN-positive tumours; grade 3 tumours: 86.8%; Ki-67>20%: 89.6%; TNBC: 72.6%; confirmed gBRCA1/2 mutation: 56.2%. The pCR rate with PO was 55.1% [90% confidence interval (CI) 44.5% to 65.3%] versus PCb 48.6% (90% CI 34.3% to 63.2%). Analysis for the stratified subgroups showed higher pCR rates with PO in the cohorts of patients <40 years and HR patients. Conclusion: GeparOLA could not exclude a pCR rate of <= 55% in the PO arm. PO was significantly better tolerated and the combination merits further evaluation.

Published
2021

49. Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA

Author

Marme, F., Hanusch, C., Furlanetto, J., Denkert, C., Link, T., Untch, M., Blohmer, J-U., Jackisch, C., Reinisch, M., Rhiem, K. E., Schneeweiss, A., Solbach, C., Schoellhorn, L., Fasching, P. A., Rey, J., Loibl, S., Marme, F., Hanusch, C., Furlanetto, J., Denkert, C., Link, T., Untch, M., Blohmer, J-U., Jackisch, C., Reinisch, M., Rhiem, K. E., Schneeweiss, A., Solbach, C., Schoellhorn, L., Fasching, P. A., Rey, J., and Loibl, S.

Published
2021

50. Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto

Author

Labidi-Galy, S. I., Schneeweiss, A., Sinn, H. P., Blohmer, J-U., Romanens, L., Zahm, D-M., Huober, J., Dohnal, D., Link, T., Hanusch, C., Jackisch, C., Fasching, P. A., Solbach, C., Rhiem, K. E., Denkert, C., Weber, K. E., Lederer, B., Untch, M., Loibl, S., Furlanetto, J., Labidi-Galy, S. I., Schneeweiss, A., Sinn, H. P., Blohmer, J-U., Romanens, L., Zahm, D-M., Huober, J., Dohnal, D., Link, T., Hanusch, C., Jackisch, C., Fasching, P. A., Solbach, C., Rhiem, K. E., Denkert, C., Weber, K. E., Lederer, B., Untch, M., Loibl, S., and Furlanetto, J.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results